Cell Signaling Global Market Report 2024

The cell signaling market size has grown strongly in recent years. It will grow from $4.25 billion in 2023 to $4.59 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to the expansion of regenerative medicine, growth of the pharmaceutical and biotechnology industries, rising burden of chronic diseases, aging population and personalized medicine initiatives.

The cell signaling market size is expected to see strong growth in the next few years. It will grow to $6.32 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. The anticipated growth during the forecast period can be credited to the expanding embrace of precision medicine, governmental backing, augmented research funding, contributions to development and homeostasis, and the surge in endocrine-related ailments. Significant trends expected during the forecast timeframe encompass technological progressions, integration of machine learning and artificial intelligence into signal analysis, utilization of bioprinting technology, next-generation sequencing, and adoption of the single-cell analysis technique.

The rising incidence of chronic diseases is anticipated to drive the expansion of the cell signaling market in the future. Chronic diseases are enduring medical conditions characterized by slow progression and extended duration, often persisting for years or a lifetime. These ailments necessitate ongoing management and treatment to mitigate symptoms, prevent complications, and uphold the quality of life. Factors contributing to the prevalence of chronic diseases include an aging populace, unhealthy lifestyles, and the availability and structure of healthcare systems. Cell signaling research furnishes valuable insights and tools for comprehending, diagnosing, treating, and preventing chronic diseases, offering prospects for enhanced outcomes and quality of life for affected individuals. For example, as per the National Library of Medicine, the projected number of individuals aged 50 and above afflicted with at least one chronic ailment is slated to surge from 71.522 million in 2020 to 142.66 million in 2050, marking a 99.5% increase. Consequently, the escalating prevalence of chronic diseases is propelling the growth of the cell signaling market.

Major corporations within the cell signaling market are concentrating on pioneering technologies, such as immunohistochemistry (IHC) assays, to fortify their market presence. Immunohistochemistry (IHC) assays are laboratory methodologies utilized to identify and visualize specific proteins or antigens present in tissue samples. For example, in September 2023, Cell Signaling Technology (CST), a US-based company specializing in life sciences discovery technology, introduced the SignalStar Multiplex IHC technology. This cutting-edge tool offers a spatial biology research method employing mid-plex, high-throughput immunohistochemistry (IHC) assays. This advancement enables researchers to simultaneously identify multiple targets within formalin-fixed, paraffin-embedded (FFPE) tissues with exceptional sensitivity and precision. By leveraging a blend of antibodies, oligonucleotides, and fluorophores, this innovative technology enhances antibody signal amplification, facilitating the detection of targets, including those with low expression levels, of up to eight proteins within a single tissue sample.

In November 2021, Merck, a pharmaceutical company headquartered in the United States, purchased Acceleron Pharma Inc. for an undisclosed amount. This acquisition is part of Merck's strategy to enhance its cardiovascular portfolio and pipeline by utilizing Acceleron's pioneering research on proteins within the transforming growth factor (TGF) beta superfamily. Acceleron Pharma Inc., a biopharmaceutical company also based in the United States, specializes in the development of medications that target proteins within the transforming growth factor beta (TGF-β) superfamily.

Major companies operating in the cell signaling market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bayer AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Agilent Technologies Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Bio-Techne Corporation, Miltenyi Biotec, Promega Corporation, Janssen Pharmaceuticals Inc., Abcam plc, Horizon Discovery Ltd., Cell Signaling Technology Inc., Cisbio Bioassays, Rockland Immunochemicals Inc.

North America was the largest region in the cell signaling market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell signaling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cell signaling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cell signaling, alternatively termed cell communication or cellular signaling, depicts the mechanism through which cells interact with one another to control diverse physiological functions, synchronize cellular activities, and react to external triggers. This complex system enables cells to perceive alterations in their surroundings, transmit signals, and prompt suitable reactions to uphold homeostasis and guarantee the optimal operation of tissues and organs.

The primary offerings within the cell signaling market encompass consumables and instruments. Consumables, in this context, denote materials or substances utilized in experiments or procedures, such as antibodies, reagents, and assay kits. Diverse signaling types comprise endocrine signaling, paracrine signaling, autocrine signaling, synaptic signaling, and other signaling variants, along with multiple pathways such as the Akt signaling pathway, AMPK signaling pathway, ERBB/HER signaling pathway, and additional signaling pathways. An array of technologies is involved, including microscopy, western blotting, flow cytometry, immunohistochemistry (IHC), ELISA, mass spectrometry, and other technologies, while applications span research and medical domains.

The cell signaling market research report is one of a series of new reports that provides cell signaling market statistics, including cell signaling industry global market size, regional shares, competitors with a cell signaling market share, detailed cell signaling market segments, market trends, and opportunities, and any further data you may need to thrive in the cell signaling industry. This cell signaling research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cell signaling market includes revenues earned by entities by providing services such as cell signaling pathway analysis, cell signaling assays, drug discovery and development, and cell signaling research. The market value includes the value of related goods sold by the service provider or included within the service offering. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.